Acumen Pharmaceuticals To Present Patient Experience And Biomarker Insights From Phase 1 INTERCEPT-AD Study At The Alzheimer's Association International Conference 2024

7/11/24 8:20:25 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ABOS alert in real time by email

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the Company will present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference (AAIC®) 2024 taking place in Philadelphia and online from July 28 – Aug. 1, 2024. The posters expand upon biomarker data associated with sabirnetug, methods for detecting levels of sabirnetug in cerebrospinal fluid (CSF), and provide insights on patients' experiences in the INTERCEPT-AD study to inform future clinical trial considerations for sabirnetug.

Get the next $ABOS alert in real time by email

Date	Price Target	Rating	Analyst
7/26/2024	$7.00	Buy	Citigroup
12/12/2023	$8.00	Buy	Deutsche Bank
7/20/2023	$9.00 → $14.00	Buy	BofA Securities
5/18/2023	$13.00	Overweight	Cantor Fitzgerald
7/15/2022	$15.00	Buy	BTIG Research
6/30/2022	$15.00	Buy	H.C. Wainwright
1/21/2022	$16.00 → $14.00	Neutral → Buy	B of A Securities
7/26/2021	$27.00	Buy	UBS

Acumen Pharmaceuticals To Present Patient Experience And Biomarker Insights From Phase 1 INTERCEPT-AD Study At The Alzheimer's Association International Conference 2024

Chat with this insight

Recent Analyst Ratings for
$ABOS

$ABOS
Press Releases

Fastest customizable press release news feed in the world

Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings

Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights

$ABOS
SEC Filings

SEC Form 144 filed by Acumen Pharmaceuticals Inc.

SEC Form 144 filed by Acumen Pharmaceuticals Inc.

SEC Form 10-Q filed by Acumen Pharmaceuticals Inc.

$ABOS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CFO & Chief Business Officer Zuga Matt sold $56,620 worth of shares (33,266 units at $1.70), decreasing direct ownership by 13% to 231,744 units (SEC Form 4)

Chief Executive Officer Oconnell Daniel Joseph sold $20,102 worth of shares (12,619 units at $1.59), decreasing direct ownership by 2% to 667,488 units (SEC Form 4)

Chief Legal Officer & Corp Sec Meisner Derek M sold $5,435 worth of shares (3,418 units at $1.59), decreasing direct ownership by 2% to 161,127 units (SEC Form 4)

$ABOS
Leadership Updates

Live Leadership Updates

Lucy Therapeutics Appoints Kim Drapkin as Board Chair

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors

$ABOS
Financials

Live finance-specific insights

Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights

Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024

Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

$ABOS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Citigroup initiated coverage on Acumen Pharmaceuticals with a new price target

Deutsche Bank initiated coverage on Acumen Pharmaceuticals with a new price target

BofA Securities resumed coverage on Acumen Pharmaceuticals with a new price target

$ABOS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Acumen Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G filed by Acumen Pharmaceuticals Inc.

SEC Form SC 13G/A filed by Acumen Pharmaceuticals Inc. (Amendment)

Acumen Pharmaceuticals To Present Patient Experience And Biomarker Insights From Phase 1 INTERCEPT-AD Study At The Alzheimer's Association International Conference 2024

Chat with this insight

Recent Analyst Ratings for $ABOS

$ABOS Press Releases

Fastest customizable press release news feed in the world

Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings

Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights

$ABOS SEC Filings

SEC Form 144 filed by Acumen Pharmaceuticals Inc.

SEC Form 144 filed by Acumen Pharmaceuticals Inc.

SEC Form 10-Q filed by Acumen Pharmaceuticals Inc.

$ABOS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CFO & Chief Business Officer Zuga Matt sold $56,620 worth of shares (33,266 units at $1.70), decreasing direct ownership by 13% to 231,744 units (SEC Form 4)

Chief Executive Officer Oconnell Daniel Joseph sold $20,102 worth of shares (12,619 units at $1.59), decreasing direct ownership by 2% to 667,488 units (SEC Form 4)

Chief Legal Officer & Corp Sec Meisner Derek M sold $5,435 worth of shares (3,418 units at $1.59), decreasing direct ownership by 2% to 161,127 units (SEC Form 4)

$ABOS Leadership Updates

Live Leadership Updates

Lucy Therapeutics Appoints Kim Drapkin as Board Chair

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors

$ABOS Financials

Live finance-specific insights

Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights

Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024

Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

$ABOS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Citigroup initiated coverage on Acumen Pharmaceuticals with a new price target

Deutsche Bank initiated coverage on Acumen Pharmaceuticals with a new price target

BofA Securities resumed coverage on Acumen Pharmaceuticals with a new price target

$ABOS Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Acumen Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G filed by Acumen Pharmaceuticals Inc.

SEC Form SC 13G/A filed by Acumen Pharmaceuticals Inc. (Amendment)

Recent Analyst Ratings for
$ABOS

$ABOS
Press Releases

$ABOS
SEC Filings

$ABOS
Insider Trading

$ABOS
Leadership Updates

$ABOS
Financials

$ABOS
Analyst Ratings

$ABOS
Large Ownership Changes